Comparison of PAM50 Risk of Recurrence Score With Onco<i>type</i> DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

Abstract

ROR provides more prognostic information in endocrine-treated patients with ER-positive, node-negative disease than RS, with better differentiation of intermediate- and higher-risk groups.